Until now, the aging of muscle stem cells has been described as depletion: cells become fewer, and those that remain work worse. But most studies compared young and old animals, missing the transitional stage. This work sits alongside studies that examine muscle aging through MRI, fatigue without touch, and the aging of perovskite batteries: all of them look for hidden changes that accumulate before an obvious failure. Here, for the first time, the fate of cells was tracked from middle age to deep old age, revealing that the disappearance of markers does not equal the disappearance of cells.
Mice were genetically labeled so that all their muscle stem cells glowed yellow with a fluorescent protein for life. Then, at the age of 10-14 months and older than 28 months, cells were isolated and sorted by different surface proteins. The researchers compared how the cells grow in culture, how they repair damaged muscle after transplantation, and which genes they switch on. Separately, they tested the effect of drugs that kill senescent cells and of the male hormone dihydrotestosterone.
The main result: the number of labeled stem cells does not decline with age, although the share of cells with the usual marker VCAM1 falls from 12-14% to 8%. A population of cells with low or zero levels of VCAM1 and the protein Pax7 appears; these were named GERI-MuSCs. These cells remain quiescent and do not turn into muscle fibers, but when transplanted they can take part in muscle repair, though they form smaller fibers. They show elevated activity of aging-related genes, such as Cdkn2a, but lack the full set of signs of irreversible senescence. The drugs dasatinib and quercetin selectively eliminate GERI-MuSCs, while the hormone DHT restores their markers and improves regeneration.
The work changes the view of muscle aging: instead of a simple depletion of the stem cell pool, we see the emergence of a special "quiet" state that is reversible. This differs from neighboring studies where aging was described as an accumulation of damage or a loss of function. Here it is shown that some cells simply hide from standard detection methods. For science, this means that previous estimates of stem cell numbers in old muscle were too low, and the effectiveness of rejuvenating therapies might have been explained by the awakening of these hidden cells.
The field could move toward a precise molecular portrait of GERI-MuSCs: which signals keep them quiescent, and which trigger awakening. Drugs may emerge that do not kill senescent cells but wake the sleeping ones. Long-term observations will be needed to track the fate of these cells after hormone therapy and during natural aging.
The results will influence gerontology, regenerative medicine, and cell therapy for muscular dystrophies. They will also force a reconsideration of protocols for isolating stem cells from the tissues of elderly donors.
To check how GERI-MuSCs behave in chronic muscle diseases and after repeated injuries. To determine which signaling pathways specifically distinguish them from fully functional stem cells.
For stem cell biology, this is a contribution to a long-standing debate: what is stem cell aging, a loss of function or a transition into a different state? The work shows that in muscle a third path is possible: the cell remains viable and retains its potential but changes its molecular appearance. This forces a reconsideration of the criteria for aging in quiescent cells, which do not divide for most of their lives.
Mice at the age of 28 months correspond to humans of about 90 years. Yet even in such deeply old animals, stem cells retain the ability to repair muscle if they are woken up by a hormone.
In the novel "Elysium," aging people gain access to medical pods that rejuvenate tissues. The discovery of GERI-MuSCs hints that rejuvenation may work not by replacing cells but by awakening the body's own dormant reserves.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.